ARN-509
Phase 2Small molecule
ARN-509 is one of 10 small molecule programs targeting Prostatectomy. It is currently in Phase 2.
1
Indications
7
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Prostatectomy
#DrugCompanyPhaseTrials
1Leuprorelin
TakedaPhase 3
Sutent
PfizerPhase 2
Firmagon
FerringPhase 2
LHRH Agonist
RochePhase 2
Flomax
SanofiPreclinical
Ramosetron
AstellasPreclinical
ARN-509
AAragon Pharmaceuticals, Inc.
Phase 2
Vesicare
AstellasPreclinical
Acetaminophen/ibuprofen
SSeoul National University Hospital
Preclinical
Belladonna and Opium
UUniversity of Washington
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Prostate Cancer4 trials
Show 1 more trial
Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer
Completed·—·Phase 2·NCT03098836·93 enrolled
Abiraterone Acetate1 trial
Prostatectomy1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ARN-509. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAragon Pharmaceuticals, Inc.